NEW YORK, Sept. 11, 2023 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the details of an oral presentation by independent investigators on September 9, 2023 at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting held in Copenhagen, Denmark. Uveal melanoma usually shows a liver-dominant […]
Tag: Delcath
Delcath Systems (DCTH) Announces Relisting On OTCQB
NEW YORK, Sept. 13, 2017 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that its Board of Directors has approved the voluntary delisting from NASDAQ. As a result of the shareholder non-approval of its reverse stock split last week by the […]